T

*click HERE for an explanation of standardised wording to be used by Scottish Boards regarding decisions on medicines since May 2016 Link to Formulary

Medicine	Indication	NHS Board Decision*	DTC Supplement	Date
TachoSil®	Haemostasis in surgery	HOSPITAL ONLY (Liver and renal surgery)	66	Feb 2007
TachoSil®	Liver surgery	HOSPITAL ONLY	50	2005
Tacrolimus (Envarsus®) (1041/15)	Prophylaxis of transplant rejection in adult kidney or liver allograft recipients and treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.	Non formulary - absence of clinician demand This may change pending a decision by tertiary transplant centres	147	Apr 2015
Tacrolimus ointment 0.1% (Protopic®) (609/10)	Moderate to severe atopic dermatitis in adult patients (> 16 years)	GPs may prescribe under the direction of the dermatology clinic	101	Dec 10/Jan 2011
Tacrolimus ointment 0.03% (Protopic®) (608/10)	Moderate to severe atopic dermatitis in children (2 - 15 years)	GPs may prescribe under the direction of the dermatology clinic	101	Dec 10/Jan 2011
Tacrolimus (Modigraf®) (657/10)	Prophylaxis of transplant rejection in adults and paediatrics	GPs may prescribe under the direction of the renal unit or paediatrics	101	Dec 10/Jan 2011
Tacrolimus (Advagraf®) (402/07)	Immunosuppressin in kidney/liver transplant	GPs may prescribe under the direction of a tertiary Transplant Centre	72	Sept 2007
Tacrolimus (Prograf®)	Heart transplant	HOSPITAL ONLY	66	Feb 2007
Tacrolimus ointment (Protopic®)	Atopic dermatitis	GPs may prescribe under the direction of Dermatology	96 Shared Care Agreement	Apr/May 2010

			65 21	Jan 2007 2002
Tadalafil (Cialis®) (849/12)	Treatment of the signs and symptoms of benign prostatic hyperplasia in adult males	Not recommended	124	Feb 2013
Tadalafil (Adcirca®) (710/11)	PAH	Restricted to initiation and supply by specialists working in SPVU. Supplied via a Patient Access Scheme (PAS) (simple discount)	119 106	Aug/Sept 2012 May/June 2011
Tadalafil (Cialis®) (554/09)	Erectile dysfunction	Formulary (Severe distress - GPs on specialist advice)	117 100 91 90 26	May/June 2012 Oct/Nov 2010 July 2009 June 2009 2003
Tafamidis 61mg soft capsules (Vyndaqel®) SMC2585	For the treatment of wild-type and hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	195	December 2023
Tafamidis 61mg soft capsules (Vyndaqel®) SMC2426	For the treatment of wild-type and hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).	Not available as not recommended for use in NHS Scotland	188	April 2022
Tafamidis 61mg soft capsules (Vyndaqel®) SMC2354	For the treatment of wild-type and hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).		186	Sept 2021
Tafamidis meglumine (Vyndaqel®) (877/13)	Treatment of transthyretin amyloidosis in adults with stage 1 symptomatic polyneuropathy	Not recommended	127	May 2013
Tafasitamab powder for concentrate for solution for infusion	In combination with lenalidomide followed by tafasitamab monotherapy for the treatment of adult patients with	Not recommended	193	June 2023

(Minjuvi®) SMC2522	relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).			
Tafluprost/timolol(Taptiqom®) (1085/15)	For the reduction of intraocular pressure in adult patients with open angle glaucoma or ocular hypertension who are insufficiently responsive to topical monotherapy with beta-blockers or prostaglandin analogues and require a combination therapy, and who would benefit from preservative-free eye drops.	Non-Formulary - lack of clinician support	151	Sep/Oct 2015
Tafluprost (Saflutan®) (581/09)	Elevated intraocular pressure	Non-formulary	94	Dec 09/Jan 10
talazoparib hard capsules (Talzenna®) SMC2753	In combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. Talazoparib offers an additional treatment choice in the therapeutic class of poly ADP-ribose polymerase inhibitors given in combination with a hormonal agent for this indication. Another medicine combination within this therapeutic class has been accepted under the end of life and orphan equivalent process for this indication.	Available in line with national guidance.		
Talazoparib 0.25mg/1mg hard capsules (Talzenna®) SMC2325	As monotherapy for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo) adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy or be considered unsuitable for endocrine-based therapy.	Not available as not recommended for use in NHS Scotland Available in line with national guidance	183 197	March 2021

Talazoparib hard capsules (Talzenna®) SMC2607	As monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer.			May/June 2024
Talimogene laherparepvec, 106 and 108 plaque forming units (PFU)/mL solution for injection (Imlygic®) SMC No: (1248/17)	Treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease.	Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts – decision expected by Sep 2017	162	Aug 2017
Talquetamab solution for injection (Talvey®) SMC2705	As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.	Not recommended for use in NHS Scotland	198	NYP
Tamsulosin (Flomaxtra XL®)	Benign prostatic hypertrophy	Non-formulary	53	2005
Tapentadol (Palexia®) (773/12)	Moderate to severe acute pain in adults	Not recommended	115	Mar/Apr 2012
Tapentadol (Palexia® SR) (654/10)	Severe chronic pain in adults	GPs may prescribe under the direction of the Pain Clinic	110 107	Oct 2011 Jul 2011
tebentafusp concentrate for solution for infusion (Kimmtrak®)	as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with	Not available as not recommended for use in NHS		

SMC2746	unresectable or metastatic uveal melanoma. Tebentafusp improved overall survival compared with investigator's choice of treatment, in (HLA)-A*02:01-positive adults with unresectable or metastatic uveal melanoma. The submitting company's justification of the treatment's cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis to gain acceptance by SMC.	Scotland		
Teclistamab solution for injection (Tecvayli®) SMC2668	As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.	Available in line with national guidance		
Tedizolid phosphate (Sivextro®) (1080/15)	Use in patients with ABSSSI caused by Gram-positive Staphylococcus aureus(specifically methicillin-resistant Staphylococcus aureus [MRSA] isolates) Use of tedizolid phosphate is restricted to use as an alternative oxazolidinone antibacterial on the specific advice of local microbiologists or specialists in infectious disease.	Non-formulary	150 152	July 2015 Nov/Dec 2015
Teduglutide 5mg vial of powder and solvent for solution for injection (Revestive®) SMC 2225	For the treatment of patients age 1 year and above with short bowel syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	179	Apr 2020
Teduglutide 5mg power and solvent for solution for injection (Revestive®) 1139/16	For the treatment of patients aged one year and above with short bowel syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative	154 168	May 2016 May 2018

	SMC restriction: initiation in paediatric patients (aged 1 to 17 years).	medicines		
Tegafur/gimeracil/oteracil (Teysuno®) (802/12)	Treatment of advanced gastric cancer when given in combination with cisplatin.	Patients unsuitable for first-line triple therapy: Non-formulary - absence of clinician support Patients suitable for first-line triple therapy: Not recommended	120	Oct 2012
Telaprevir (Incivo®) (Exp) (742/11)	Genotype I chronic hepatitis C	HOSPITAL ONLY (Hepatitis Clinic)	113	Jan 2012
Telaprevir (Incivo®) (Naive) (743/11)	Genotype I chronic hepatitis C	HOSPITAL ONLY (Hepatitis Clinic)	113	Jan 2012
Telavancin hydrochloride (Vibativ®) (1015/14)	Adults with nosocomial pneumonia (NP) including ventilator associated pneumonia, known or suspected to be caused by methicillin-resistant Staphylococcus aureus (MRSA)	Not recommended	143	Nov/Dec 2014
Telbivudine (Selbivo®) (438/08)	Chronic hepatitis B	Non-formulary	79 77	May 2008 Mar 2008
Telmisartan (Micardis®) (631/10)	Cardiovascular prevention or type 2 diabetes mellitus	Not recommended	96	Apr/May 2010
Telmisartan/ hydrochlorothiazide (MicardisPlus®)	Hypertension		26	2003
Telotristat ethyl 250mg film-coated tablets (Xermelo®) SMC No 1327/18	Treatment of carcinoid syndrome diarrhoea in combination with somatostatin analogue therapy in adults inadequately controlled by somatostatin analogue therapy. SMC restriction: patients with CS diarrhoea who experience an average of four or more bowel motions per day, despite receiving somatostatin analogue therapy.	Available in line with National guidance GPs under the direction of Neuroendocrine and Oncology clinic. Telotristat protocol	169	July 2018
Temsirolimus (Torisel®) (617/10)	Adult patient with relapsed and/or refractory mantle cell lymphoma (MCL)	Not recommended	96	Apr/May 2010

Temsirolimus (Torisel®)	Advanced renal cell carcinoma	Not commercially available	82	Aug/Sept 2008
Temoporfin (Foscan®)	Advanced head and neck squamous cell carcinoma		39	2004
Temozolomide (Temodal®)	Newly diagnosed glioblastoma multiforme (GBM) High grade glioblastoma multiforme (GBM)	HOSPITAL ONLY	64 56	2006
tenecteplase 5,000 units (25 mg) powder for solution for injection (Metalyse®) SMC2697	in adults for the thrombolytic treatment of acute ischaemic stroke within 4.5 hours from last known well and after exclusion of intracranial haemorrhage.	Available in line with local guidance		
Tenofovir alafenamide 25mg film-coated tablets (Vemlidy®) (1238/17)	Treatment of chronic hepatitis B in adults and adolescents (aged 12 years and older with body weight at least 35 kg)	Not available as not recommended for use in NHS Scotland	161	Jun 2017
Tenofovir disoproxil fumarate (Viread®) (905/13)	HIV-1	HOSPITAL ONLY Paediatrics under supervision of HIV specialists in Glasgow and Edinburgh	130	Sept/Oct 2013
Tenofovir disoproxil fumarate (Viread®) (900/13)	HIV-1	HOSPITAL ONLY Paediatrics under supervision of HIV specialists in Glasgow and Edinburgh	130	Sept/Oct 2013
Tenofovir disoproxil fumarate (Viread®) (904/13)	HIV-1	HOSPITAL ONLY Paediatrics under supervision of HIV specialists in Glasgow and Edinburgh	130	Sept/Oct 2013
Tenofovir disoproxil fumarate (Viread®) (720/11)	Chronic hepatitis B in adults with compensated liver disease	HOSPITAL ONLY (Hepatitis Clinic)	110 86 81	Oct 2011 Jan/Feb 2009 Jul 2008
Tenofovir (Viread®)	HIV/AIDS		20	2002
Tepotinib 225mg film-coated tablets (Tepmetko®) SMC2535	For the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (metex14) skipping alterations. In a phase II single-arm study in adults with advanced	Available in line with national guidance	192	April 2023

	NSCLC with metex14 skipping mutations, tepotinib was associated with an objective response rate of 51%.			
Tepotinib 225mg film-coated tablets (Tepmetko®) SMC2457	For the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping alterations. In a phase II study in adults with advanced NSCLC with METex14 skipping mutations, tepotinib was associated with a clinically relevant response rate.	Not available as not recommended for use in NHS Scotland		
Teriflunomide (Aubagio®) (940/14)	Adults with relapsing remitting multiple sclerosis (MS) as an alternative to treatment with interferon beta or glatiramer acetate	Available in line with local guidance for prescribing	136	Mar/Apr 2014
Teriparatide (Forsteo®) 750mcg/3ml solution for injection (490/08)	Osteoporosis in men at increased risk of fracture	Not recommended	82	Aug/Sept 2008
Teriparatide (Forsteo®) 20mcg/80mcl solution for injection (487/08)	Osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk of fracture	Not recommended	80	June 2008
Teriparatide (Forsteo®)	Severe osteoporosis	HOSPITAL ONLY	104 Protocol 49 35	2003
Terlipressin acetate (Glypressin® Solution) (555/09)	Bleeding oesophageal viraces	HOSPITAL ONLY	91	Jul 2009
Testosterone 20mg/g transdermal gel (Testavan®) SMC2152	Testosterone replacement therapy for adult male hypogonadism, when testosterone deficiency has been confirmed by clinical features and biochemical tests. SMC restriction: patients requiring a transdermal delivery system	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	174	May 2019
Testosterone transdermal patch (Intrinsa TTP®)	Hypoactive sexual desire disorder (HSDD) post surgically induced menopause	Not recommended	72	Sept 2007

Testosterone gel (Tostran®) (372/07)	Male hypogonadism	GPs may prescribe under the direction of the Endocrine Clinic	69	June 2007
Testosterone injection (Nebido®)	Hypogonadism	GPs may prescribe under the direction of the Endocrine Clinic	87 60	Mar 2009 2006
Testosterone 50mg/5g gel (Testim®)	Hypogonadism	Non-formulary	116 60	Apr/May 2012 2006
Testosterone buccal tablets (Striant SR®)	Hypogonadism	Non-formulary	116 46	Apr/May 2012 2004
Testosterone gel (Testogel®)	Hypogonadism	GPs may prescribe under the direction of the Endocrine Clinic	116 34	Apr/May 2012 2003
Tetracaine/lidocaine (Pliaglis® 70 mg/g + 70 mg/g cream (1000/14)	Local dermal anaesthesia on intact skin prior to dermatological procedures in adults	Not recommended	141	Sept/Oct 2014
Tezacaftor-ivacaftor (Symkevi), Vertex Pharmaceuticals Europe Ltd. SMC2711	in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (CF) aged 6 years and older who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272-26A→G, and 3849+10kbC→T.	Available in line with national guidance		
Tezacaftor and ivacaftor 100mg/150mg film-coated tablets (Symkevi®) SMC2183	In a combination regimen with ivacaftor 150mg tablets for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: P67L, R117C, L206W, R352Q, A455E,	Not available as not recommended for use in NHS Scotland	176	Oct 2019

	D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272-26A→G, and 3849+10kbC→T.			
Tezepelumab solution for injection in pre-filled syringe (Tezspire®) SMC2541	As an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment. SMC restriction: in adults and adolescents 12 years and older who either (i) experienced at least three exacerbations in the previous year and are not receiving maintenance treatment with oral corticosteroids or (ii) have blood eosinophils ≥150 cells/microlitre and are receiving maintenance treatment with oral corticosteroids.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	194	September 2023
Thalidomide (Thalidomide Pharmion®) (525/08)	Multiple myeloma	HOSPITAL ONLY (Haematology)	108 Protocol 86	Aug 2011 Jan 2009
Thiotepa (Tepadina®) (790/12)	In combination with other chemotherapy medicinal products	Not recommended	119	Aug/Sept 2012
Ticagrelor 60mg film-coated tablets (Brilique®) (1224/17)	Co-administered with acetylsalicylic acid for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction and a high risk of developing an atherothrombotic event.	Not available as not recommended for use in NHS Scotland	161	Jun 2017
Ticagrelor (Brilique®) (699/11)	Prevention of atherothrombotic events	GPs may prescribe under the direction of the Cardiology Clinic	124 122 113 106	Feb 2013 Dec 2012 May/June 2011
Tigecycline (Tygacil®) (1101/15)	Treatment in children from the age of eight years for the following infections: - complicated skin and soft tissue infections, excluding diabetic foot infections complicated intra-abdominal infections.	Not recommended	151	Sep/Oct 2015
Tigecycline (Tygacil®)	Complicated skin and soft-tissue infections		105 60	Apr/May 2011 2006

Tigecycline (Tygacil®)	Complicated intra-abdominal infection (cIAI)		105 60	Apr/May 2011 2006
Tildrakizumab 100mg solution for injection in pre-filled syringe (Ilumetri®) SMC2167	The treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.	Available in line with local guidance for prescribing	177	Dec 2019
Timolol (Tiopex®) (941/14)	Reduction of elevated intraocular pressure	Non-formulary - alternatives preferred	135	Feb/Mar 2014
Timothy grass pollen allergen (GRAZAX) (868/13)	Disease-modifying treatment of grass pollen induced rhinitis and conjunctivitis	Not recommended	127	May 2013
Tinzaparin (Innohep Syringe®) (1061/15)	Patients with solid tumours: Extended treatment of symptomatic venous thrombo-embolism (VTE) and prevention of its recurrence.	Non Formulary pending specialist decision	150	June 2015
Tiotropium 2.5 microgram solution for inhalation (Spiriva® Respimat®) SMC2118	As add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year. Tiotropium has been accepted for use in adult patients with asthma as add-on maintenance bronchodilator treatment	Available in line with national guidance (link to SMC advice)	173	March 2019
Tiotropium/olodaterol (Spiolto® Respimat®) (1099/15)	Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).	Formulary	152	Nov/Dec 2015
Tiotropium (Spiriva® Respimat®) (1028/15)	As add-on maintenance bronchodilator treatment in adult patients with asthma who are currently treated with the maintenance combination of inhaled corticosteroids (≥800 micrograms budesonide/day or equivalent) and long-acting beta2 agonists and who experienced one or more severe exacerbations in the previous year.	Formulary GP prescribing under direction of respiratory clinic (Respiratory Specialist formulary list)	150	July 2015
Tiotropium 2.5 microgram	As a maintenance bronchodilator treatment to relieve	Not routinely available as local	166	Feb 2018

inhalation solution (Spiriva Respimat®) SMC No 411/07	symptoms of patients with chronic obstructive pulmonary disease (COPD).	clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	100 Further info 75	Oct/Nov 2010 Dec 2007
Tiotropium (Spiriva®)	Chronic obstructive pulmonary disease	Formulary	100 Further info 23	Oct/Nov 2010 2002
Tipranavir (Aptivus®) (oral solution) (602/10)	HIV-1		95 61 55	Feb/Mar 2010 2006
Tipranavir (Aptivus®) (soft capsule) (616/10)	HIV-1	Available from a specialist centre in another NHS Board	95	Feb/Mar 2010
Tirbanibulin 10mg/g ointment (Klisyri®) SMC2395	Field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	188	April 2022
Tirzepatide solution for injection in pre-filled pen (Mounjaro) SMC2653	For weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial Body Mass Index (BMI) of ≥30 kg/m2 (obesity) or ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).	Not routinely available as local implemetation plans are being developed or the ADTC is waiting for advice from local clinical expert - decision expected by June 2025.	198 not yet published	
tirzepatide solution for injection in pre-filled pen (Mounjaro) SMC 2633	For the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise: •as monotherapy when metformin is considered inappropriate due to intolerance or contraindications	Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts - decision	197	May/June 2024

	•in addition to other medicinal products for the treatment of diabetes.	expected by August 2024m Ore information available July 2025		
Tisagenlecleucel 1.2 x 106 to 6 x 108 cells dispersion for infusion (Kymriah®) SMC2200	For adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.	Available from a specialist centre in another NHS Board	177	Dec 2019
Tisagenlecleucel 1.2 x 106 to 6 x 108 cells dispersion for infusion (Kymriah®) SMC2141	For adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Tisagenlecleucel was associated with an overall response rate of 53% in a single-arm, open-label, phase II study in patients with relapsed or refractory DLBCL.	Not available as not recommended for use in NHS Scotland		
Tisagenlecleucel 1.2 x 106 – 6 x 108 cells dispersion for infusion (Kymriah®) SMC2129	Treatment of paediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse.	Available from a specialist centre in another NHS Board	174	May 2019
Tixagevimab and cilgavimab (Evusheld®) Astra Zeneca UK Limited SMC2558	treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.	Not recommended for use in NHS Scotland	197	May/June 2024
Tixagevimab plus cilgavimab for preventing COVID-19 SMC2580	The product has been considered within its marketing authorisation for preventing coronavirus disease 2019 (COVID-19), and this recommendation is valid for NHSScotland.		194	September 2023
Tivozanib 890 micrograms and 1,340 micrograms hard capsules, (Fotivda®) SMC No 1335/18	The first-line treatment of adult patients with advanced renal cell carcinoma and for adult patients who are vascular endothelial growth factor receptor and mammalian target of rapamycin pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced renal cell carcinoma (RCC). SMC restriction: to first-line treatment of advanced RCC.	Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts- decision expected by October 2018	170	Sep 2018
Tobramycin (TOBI Podhaler®)	Chronic pulmonary infection due to Pseudomonas	GPs may prescribe under the	119	Aug/Sept 2012

(783/12)	aeruginosa in adults and children aged 6 years and older with cystic fibrosis	direction of Adult/Paed CF Clinic	118	July 2012
Tobramycin (Bramitob®)	Chronic pulmonary infection (patients with CF aged 6 years and over)	GPs may prescribe under the direction of the Cystic Fibrosis Clinic	87	Mar 2009
Tocilizumab, 162mg solution for injection in pre-filled syringe and pre-filled pen (RoActemra®) SMC2014	The treatment of Giant Cell Arteritis (GCA) in adult patients SMC restriction: treatment with tocilizumab is subject to a 12 month clinical stopping rule.	Available in line with local guidance for prescribing .	171	Oct 2018
Tocilizumab 162mg solution for injection in Pre-Filled Syringe (RoActemra®) SMC 1201/16	Treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.	Not available as not recommended for use in NHS Scotland.	158	Dec 2016
Tocilizumab (RoActemra®) (1020/14)	Rheumatoid arthritis	Not recommended	144	Jan/Feb 2015
Tocilizumab (RoActemra®) (982/14)	Moderate to severe active rheumatoid arthritis in adults in combination with methotrexate	HOSPITAL ONLY (Rheumatology)	140	Jul/Aug 2014
Tocilizumab (RoActemra®) (930/13)	Juvenile idiopathic arthritis	HOSPITAL ONLY (Paediatric Rheumatology Clinic)	134	Jan/Feb 2014
Tocilizumab (RoActemra®) (754/12)	Active systemic juvenile idiopathic arthritis	HOSPITAL ONLY (Paediatric Rheumatology Clinic)	115	Mar/Apr 2012
Tocilizumab (RoActemra®) (593/09)	Moderate to severe active rheumatoid arthritis in adults in combination with methotrexate	HOSPITAL ONLY (restricted for use in combination therapy)	100 94	Oct/Nov 2010 Dec 09/Jan 10
Tocilizumab (RoActemra®) (774/12)	Moderate to severe active rheumatoid arthritis in adults - monotherapy	HOSPITAL ONLY (Rheumatology Clinic) (Restricted to use in accordance with BSR guidance)	120 117	Oct 2012 May/June 2012
Tocilizumab (RoActemra®) SMC2552	Treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.	Available in line with national guidance		March 2023
Tocofersolan (Vedrop®) (696/11)	Vitamin E deficiency	Not recommended	121	Nov 2012

			106	May/June 2011
Tofacitinib 5mg film-coated tablets (Xeljanz®) SMC2463	For the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	191	Nov 2022
Tofacitinib 5mg, 10mg film-coated tablets (Xeljanz®) SMC2122	For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	174	May 2019
Tofacitinib, 5mg film-coated tablet (Xeljanz®) SMC2116	In combination with methotrexate for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy. SMC restriction: for use in patients with psoriatic arthritis whose disease has not responded adequately to at least two conventional DMARDs, given either alone or in combination	Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts- decision expected by May 2019	173	March 2019
Tofacitinib citrate 5mg film-coated tablets (Xeljanz®) SMC No 1298/18	In combination with methotrexate for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Tofacitinib can be given as monotherapy in case of intolerance to methotrexate or when treatment with methotrexate is inappropriate. SMC restriction: In patients with severe disease (a disease activity score [DAS28] greater than 5.1) that has	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	167	April 2018

	not responded to intensive therapy with a combination of conventional DMARDs. In patients with severe disease inadequately controlled by a tumour necrosis factor (TNF) antagonist, it may be used in patients ineligible to receive rituximab.			
Tolvaptan 15mg, 30mg, 45mg, 60mg and 90mg tablets (Jinarc®) SMC No. 1114/15	To slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with chronic kidney disease stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease.	Available in line with National Guidance - Hospital Use only (Renal clinic)	153	Jan/Feb 2016
Tolvaptan (Samsca®) (605/10)	Hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH)	Not recommended	94	Dec 09/Jan 10
Topiramate (Topamax®)	Migraine prophylaxis	GPs may prescribe under the direction of the Neurology Clinic	61 Protocol	2006
Topiramate (Topamax®)	Epilepsy	GPs may prescribe under the direction of a Neurologist	50 35	2004
Topotecan (Hycamtin®) (421/07)	Carconoma of the cervix	Not recommended	75	Dec 2007
Topotecan (Hycamtin®) (545/09)	Relapsed small cell lung cancer (SCLC)	HOSPITAL ONLY (Oncology)	108 Protocol 88 68	Aug 2011 Apr 2009 May 2007
Trabectedin 0.25mg and 1mg powder for concentrate for solution for infusion (Yondelis®) SMC2283	Treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	182	January 2021
Trabectedin 0.25mg and 1mg powder for concentrate for solution for infusion (Yondelis®) SMC 2210	Treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.	Not available as not recommended for use in NHS Scotland	178	Feb 2020

Trabectedin (Yongelis®) (634/10)	Relapsed platinum-sensitive ovarian cancer	Not recommended	99	Aug/Sept 2010
Trabectedin (Yondelis®) (452/08)	Advanced soft tissue sarcoma	Not recommended	109 100 82 77	Sept 2011 Oct/Nov 2010 Aug/Sept 2008 Mar 2008
Tralokinumab 150mg solution for injection in pre-filled syringe (Adtralza®) LEO Pharma SMC2403	Treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy. SMC restriction: patients who have had an inadequate response to an existing systemic immunosuppressant such as ciclosporin, or in whom such treatment is considered unsuitable.	Available in line with local guidance for prescribing	188	April 2022
Trastuzumab deruxtecan powder for concentrate for solution for infusion (Enhertu®) SMC2693	As monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.	Not recommended for use in NHS Scotland	198 not yet published	
Trastuzumab deruxtecan, 100mg powder for concentrate for solution for infusion (Enhertu®) SMC2545	As monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.	Available in line with national guidance		
Trifarotene 50 microgram/g cream (Aklief®) SMC2441	For the cutaneous treatment of acne vulgaris of the face and/or the trunk in patients from 12 years of age and older, when many comedones, papules and pustules are present. Trifarotene provides an additional treatment choice in the therapeutic class of topical retinoids.	Available in line with local guidance for prescribing	191	Nov 2022
Trifluridine/tipiracil 15mg/6.14mg and 20mg/8.19mg film-coated tablets (Lonsurf®) SMC2329	As monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease. SMC restriction: for use as third line treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	185	Awaiting Publication

	gastroesophageal junction. In a phase III, randomised, double-blind study, trifluridine/tipiracil was associated with an improvement in overall survival compared with placebo.			
Tramadol/paracetamol (Tramacet®)	Moderate to severe pain	Not recommended	55	2006
Trametinib 0.5mg, 2mg film-coated tablets (Mekinist®) SMC2328	In combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. SMC restriction: after first line treatment Trametinib in combination with dabrafenib offers an additional treatment choice in the therapeutic class of BRAF/ mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors. Another medicine combination within this therapeutic class has been accepted via the end of life and orphan medicine process.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	184	May 2021
Trametinib 0.5mg, 2mg film-coated tablets (Mekinist®) SMC No. (1264/17)	Un combination with dabrafenib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.	Not available as not recommended for use in NHS Scotland	163	Sep 2017
Trametinib 0.5mg and 2mg film-coated tablets (Mekinist®) SMC 1161/16	In combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	157	Nov 2016
Trastuzumab deruxtecan powder for concentrate for solution for infusion (Enhertu®) SMC2706	As monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours have an activating HER2 (ERBB2) mutation and		198	NYP

	who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.			
Trastuzumab deruxtecan (Enhertu) SMC2608	As monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	196 – awaiting publication	Feb 2024
Trastuzumab deruxtecan (Enhertu) Daiichi Sankyo UK Ltd SMC2388	As monotherapy for the treatment of adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received two or more prior anti-HER2-based regimens.	Available in line with national guidance	188	April 2022
Trastuzumab emtansine 100mg and 160mg powder for concentrate for solution for infusion (Kadcyla®) SMC2298	As a single agent, for the adjuvant treatment of adult patients with human epidermal growth factor-2 (HER2) positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2 targeted therapy.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	182	January 2021
Trastuzumab emtansine, 100mg and 160mg, powder for concentrate for solution for infusion (Kadcyla ®) (990/14)	As a single agent, for the treatment of adult patients with human epidermal growth factor type 2 (HER2)-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy.	Available in line with national guidance	142 161	Oct/Nov 2014 Jun 2017
Trastuzumab (Herceptin®) (928/13)	HER2 positive metastatic breast cancer (MBC) and early breast cancer (EBC)	HOSPITAL ONLY (Haematology/Oncology)	134	Jan/Feb 2014
Trastuzumab (Herceptin®) (623/10)	HER2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction	Available in line with national guidance	103 152 157	Feb/Mar 2011 Nov/Dec 2015 Nov 2016
Trastuzumab (Herceptin®)	HER2 positive early breast cancer	Not recommended	99	Aug/Sept 2010

			71 60	July 2007 2006
Travoprost/timolol eye drops (Duotrav®)	Glaucoma/ocular Hypertension	Non-formulary	60	2006
Travoprost (Travatan®) (1091/15)	Decrease of elevated intraocular pressure in paediatric patients aged 2 months to <18 years with ocular hypertension or paediatric glaucoma.	Formulary - GP under direction of ophthalmology/ paediatrics	152	Nov/Dec 2015
Travoprost eye drops (Travatan®)	Glaucoma		36	2004
Treosulfan powder for solution for infusion (Trecondi®) SMC2527	in combination with fludarabine as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with malignant and non-malignant diseases, and in paediatric patients older than one month with malignant diseases.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	194	September 2023
Triamcinolone (Hexacetonide®) (1103/15)	Juvenile idiopathic arthritis (JIA).	Formulary - Hospital Use Only (Paediatric rheumatology and orthopaedics)	152	Nov/Dec 2015
Trientine tetrahydrochloride (equivalent to 150 mg trientine) film-coated tablets (Cuprior®) SMC2222	The treatment of Wilson's disease in adults, adolescents and children ≥5 years intolerant to D-penicillamine therapy.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	178	Feb 2020
trifarotene 50 microgram/g cream (Aklief®) SMC2441	for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy.			
Trifluridine/tipiracil film-coated tablets (Lonsurf®) SMC2654	in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents.	Available in line with national guidance	198	NYP

Trifluridine/tipiracil 15mg/6.14mg and 20mg/8.19mg film-coated tablets (Lonsurf®) SMC2329	As monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease. SMC restriction: for use as third line treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction. In a phase III, randomised, double-blind study, trifluridine/tipiracil was associated with an improvement in overall survival compared with placebo.	Available in line with national guidance	185	July 2021
Trifluridine/tipiracil (as hydrochloride) (Lonsurf®) (1221/17)	Treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vascular endothelial growth factor agents, and anti-epidermal growth factor receptor agents.	Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts - decision expected by June 2017	160	Apr 2017
Triptorelin sustained-release 3mg powder for suspension for injection (Decapeptyl SR®) SMC2186	As adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine responsive early stage breast cancer in women at high risk of recurrence who are confirmed as premenopausal after completion of chemotherapy.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	177	Dec 2019
Triptorelin pamoate (Salvacyl®) (796/12)	Reversible reduction of testosterone to castrate levels in order to decrease sexual drive in adult men	Not recommended	118	July 2012
Triptorelin (Gonapeptyl Depot®)	Central precocious puberty	Not recommended	50	2005
Triptorelin 22.5mg (Decapeptyl SR®) (705/11)	Locally advanced non-metastatic prostate cancer and metastatic prostate cancer	GPs may prescribe under the direction of the Urology/Oncology Clinic	107	July 2011
Triptorelin 11.25mg (Decapeptyl SR®)	Prostate cancer	GPs may prescribe under the direction of the Urology	55 42	2006 2004

		Clinic		
Triptorelin 11.25mg (Decapeptyl SR®)	Endometriosis	GPs may prescribe under the direction of a Gynaecologist	54	2005
Triptorelin (Gonapeptyl® depot)	Prostate cancer	Not recommended	58	2006
Triptorelin (Gonapeptyl® depot)	Endometriosis	Not recommended	58	2006
Triptorelin 11.25mg (Decapeptyl SR®)	Precocious puberty	HOSPITAL ONLY (Paediatric Endocrine Clinic)	64	2006
Trospium chloride (Flotros®) (600/10)	Urge incontinence and/or increased urinary frequency and urgency	Non-formulary	95	Feb/Mar 2010
Tucatinib (Tukysa) Seagen Inc SMC2398	In combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least two prior anti-HER2 treatment regimens.	Available in line with national guidance	188	April 2022

Updated: 5th June 2025

Back to top Back to homepage